5 Aptamer-Based Medical Devices
127
in the field of medical device whose reliable results are the first priority. Nevertheless, the development of antibody technology in the field of medical devices is also
worth learning from due to the functional similarities with aptamer. The share in test
strips, test kits and the innovations in which aptamer integrated with other mature
technologies can be promising areas for aptamer-based medical device to occupy.
5.4.3 Seize the Opportunities
As the proverb says, “a hero is known in the time of misfortune.” Sometimes it
takes an opportunity for a technology to go from being obscure to impactful. It is a
small regret that there were no aptamer-based medical devices invented and applied
during the COVID-19 epidemic in 2020. In the future, academics should seize every
opportunity to demonstrate to the world the advantages of aptamer-based medical
devices, including reliability, efficiency, low cost, etc. We believe that in the wake
of the unremitting efforts of academics, with the continuous progress of aptamerbased technology, aptamers will have a bright future in the escalating medical device
market someday.
Acknowledgements This work was supported by the Tianjin Education Program (2019KJ082)
and the National S&T Major Project (number 2018ZX09201011).
References
1. Bergsland J, Elle OJ, Fosse E (2014) Barriers to medical device innovation. Med Dev (Auckland
NZ) 7:205–209
2. FDA (2020) Medical device overview FDA. https://www.fda.gov/industry/regulated-products/
medical-device-overview. Accessed 14 Feb 2020
3. EvaluateMedTech®, World Preview 2018, Outlook to 2024, © Evaluate Ltd
4. EvaluateMedTech®, World Preview 2016, Outlook to 2022, © Evaluate Ltd
5. FDA (2020) Pma Approvals FDA. https://www.fda.gov/medical-devices/device-approvals-den
ials-and-clearances/pma-approvals. Accessed 25 April 2020
6. Meng HM, Liu H, Kuai HL, Peng RZ, Mo LT, Zhang XB (2016) Aptamer-Integrated DNA
nanostructures for biosensing, bioimaging and cancer therapy. Chem Soc Rev 45(9):2583–2602
7. Famulok M, Hartig JS, Mayer G (2007) Functional aptamers and aptazymes in biotechnology,
diagnostics, and therapy. Chem Rev 107(9):3715–3743
8. Hermann T, Patel DJ (2000) Biochemistry−adaptive recognition by nucleic acid aptamers.
Science 287(5454):820–825
9. Zhou JH, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges.
Nat Rev Drug Discov 16(3):181–202
10. SomaLogic (2020) About−Somalogic. SomaLogic. https://somalogic.com/about-us/.
Accessed 25 April 2020
11. Jacob J, Ngo D, Finkel N, Pitts R, Gleim S, Benson MD, Keyes MJ, Farrell LA, Morgan T,
Jennings LL, Gerszten RE (2018) Application of large-scale aptamer-based proteomic profiling
to planned myocardial infarctions. Circulation 137(12):1270–1277
127
in the field of medical device whose reliable results are the first priority. Nevertheless, the development of antibody technology in the field of medical devices is also
worth learning from due to the functional similarities with aptamer. The share in test
strips, test kits and the innovations in which aptamer integrated with other mature
technologies can be promising areas for aptamer-based medical device to occupy.
5.4.3 Seize the Opportunities
As the proverb says, “a hero is known in the time of misfortune.” Sometimes it
takes an opportunity for a technology to go from being obscure to impactful. It is a
small regret that there were no aptamer-based medical devices invented and applied
during the COVID-19 epidemic in 2020. In the future, academics should seize every
opportunity to demonstrate to the world the advantages of aptamer-based medical
devices, including reliability, efficiency, low cost, etc. We believe that in the wake
of the unremitting efforts of academics, with the continuous progress of aptamerbased technology, aptamers will have a bright future in the escalating medical device
market someday.
Acknowledgements This work was supported by the Tianjin Education Program (2019KJ082)
and the National S&T Major Project (number 2018ZX09201011).
References
1. Bergsland J, Elle OJ, Fosse E (2014) Barriers to medical device innovation. Med Dev (Auckland
NZ) 7:205–209
2. FDA (2020) Medical device overview FDA. https://www.fda.gov/industry/regulated-products/
medical-device-overview. Accessed 14 Feb 2020
3. EvaluateMedTech®, World Preview 2018, Outlook to 2024, © Evaluate Ltd
4. EvaluateMedTech®, World Preview 2016, Outlook to 2022, © Evaluate Ltd
5. FDA (2020) Pma Approvals FDA. https://www.fda.gov/medical-devices/device-approvals-den
ials-and-clearances/pma-approvals. Accessed 25 April 2020
6. Meng HM, Liu H, Kuai HL, Peng RZ, Mo LT, Zhang XB (2016) Aptamer-Integrated DNA
nanostructures for biosensing, bioimaging and cancer therapy. Chem Soc Rev 45(9):2583–2602
7. Famulok M, Hartig JS, Mayer G (2007) Functional aptamers and aptazymes in biotechnology,
diagnostics, and therapy. Chem Rev 107(9):3715–3743
8. Hermann T, Patel DJ (2000) Biochemistry−adaptive recognition by nucleic acid aptamers.
Science 287(5454):820–825
9. Zhou JH, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges.
Nat Rev Drug Discov 16(3):181–202
10. SomaLogic (2020) About−Somalogic. SomaLogic. https://somalogic.com/about-us/.
Accessed 25 April 2020
11. Jacob J, Ngo D, Finkel N, Pitts R, Gleim S, Benson MD, Keyes MJ, Farrell LA, Morgan T,
Jennings LL, Gerszten RE (2018) Application of large-scale aptamer-based proteomic profiling
to planned myocardial infarctions. Circulation 137(12):1270–1277